SCHEMBL24664172

SCHEMBL24664172

CC(C)(C)OC(=O)N[C@H](Cc1nc(-c2ccc(Oc3ncc(Cl)cc3F)cc2)no1)C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 4/20 0.55
▸ KCNH2 Q12809 3/20 0.55
▸ PTPN1 P18031 2/20 0.42
▸ PPARD Q03181 5/20 0.42
▸ PPARA Q07869 5/20 0.42
▸ S1PR3 Q99500 1/20 0.42
▸ SCN9A Q15858 2/20 0.41
▸ TACR1 P25103 1/20 0.39
▸ PRSS1 P07477 1/20 0.38
▸ PRSS2 P07478 1/20 0.38
▸ PRSS3 P35030 1/20 0.38
▸ TPSAB1 Q15661 1/20 0.38
▸ BCL2 P10415 1/20 0.37
▸ CACNA1B Q00975 1/20 0.37
▸ GSTP1 P09211 1/20 0.37
▸ FFAR1 O14842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24665139 1.00 LTA4H (0.55) LTA4HKCNH2PTPN1PPARDPPARA
SCHEMBL30005937 0.92 LTA4H (0.44) LTA4HKCNH2PTPN1PPARDPPARA
SCHEMBL27204637 0.90 LTA4H (0.61) LTA4HKCNH2PTPN1S1PR3SCN9A
SCHEMBL27171405 0.90 LTA4H (0.61) LTA4HKCNH2PTPN1S1PR3SCN9A
SCHEMBL24664143 0.87 PPARD (0.43) LTA4HKCNH2PTPN1PPARDPPARA
SCHEMBL24665140 0.84 LTA4H (0.66) LTA4HKCNH2S1PR3SCN9AGSTP1
SCHEMBL30006420 0.84 LTA4H (0.66) LTA4HKCNH2S1PR3SCN9AGSTP1
SCHEMBL29123521 0.84 LTA4H (0.66) LTA4HKCNH2S1PR3SCN9AGSTP1
SCHEMBL24664173 0.84 LTA4H (0.66) LTA4HKCNH2S1PR3SCN9AGSTP1
SCHEMBL30005613 0.84 LTA4H (0.66) LTA4HKCNH2S1PR3SCN9AGSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4628163-A1 NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES Novartis AG (CH) 2025-10-08 — — EP disclosed
EP-4323062-B1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2025-07-23 — — EP disclosed
US-20240199593-A1 Novel Heteroaryl Aminopropanol Derivatives NOVARTIS PHARMA AG (CH) 2024-06-20 — — US disclosed
US-11932630-B2 Heteroaryl aminopropanol derivatives NOVARTIS AG (CH) 2024-03-19 — — US disclosed
EP-4323062-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H Novartis AG (CH) 2024-02-21 — — EP disclosed
US-20220348566-A1 Novel Heteroaryl Aminopropanol Derivatives NOVARTIS AG (CH) 2022-11-03 — — US disclosed
WO-2022219546-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2022-10-20 — — WO disclosed
WO-2022219546-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2022-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348566-A1 Novel Heteroaryl Aminopropanol Derivatives CYP11B2, CYP11B1, CYP3A43 LTA4H 953/4885KCNH2 1671/4885PTPN1 1694/4885
US-20240199593-A1 Novel Heteroaryl Aminopropanol Derivatives CYP3A43, CYP3A5, CYP51A1 LTA4H 1384/4885KCNH2 3303/4885PTPN1 1752/4885
US-11932630-B2 Heteroaryl aminopropanol derivatives CYP3A43, CYP11B2, ADRB3 LTA4H 1006/4885KCNH2 1449/4885PTPN1 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback